Gene Promoter-Methylation Signature as Biomarker to Predict Cisplatin-Radiotherapy Sensitivity in Locally Advanced Cervical Cancer.

MLA

Contreras-Romero, Carlos, et al. “Gene Promoter-Methylation Signature as Biomarker to Predict Cisplatin-Radiotherapy Sensitivity in Locally Advanced Cervical Cancer.” Frontiers in Oncology, vol. 12, Mar. 2022, p. 773438. EBSCOhost, https://doi.org/10.3389/fonc.2022.773438.

APA

Contreras-Romero, C., Pérez-Yépez, E.-A., Martinez-Gutierrez, A. D., Campos-Parra, A., Zentella-Dehesa, A., Jacobo-Herrera, N., López-Camarillo, C., Corredor-Alonso, G., Martínez-Coronel, J., Rodríguez-Dorantes, M., de León, D. C., & Pérez-Plasencia, C. (2022). Gene Promoter-Methylation Signature as Biomarker to Predict Cisplatin-Radiotherapy Sensitivity in Locally Advanced Cervical Cancer. Frontiers in Oncology, 12, 773438. https://doi.org/10.3389/fonc.2022.773438

Chicago

Contreras-Romero, Carlos, Eloy-Andrés Pérez-Yépez, Antonio Daniel Martinez-Gutierrez, Alma Campos-Parra, Alejandro Zentella-Dehesa, Nadia Jacobo-Herrera, César López-Camarillo, et al. 2022. “Gene Promoter-Methylation Signature as Biomarker to Predict Cisplatin-Radiotherapy Sensitivity in Locally Advanced Cervical Cancer.” Frontiers in Oncology 12 (March): 773438. doi:10.3389/fonc.2022.773438.